Trial Profile

Phase 3 single-arm study of RLYB212

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 27 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs RLYB 212 (Primary)
Indications Neonatal alloimmune thrombocytopenia
Focus Registrational; Therapeutic Use

Most Recent Events

27 Jun 2023 New trial record
24 Jun 2023 According to a Rallybio media release, Natural History Study will establish the operational framework for seamless initiation of the Phase 2 study and future Phase 3 registrational study.
24 Jun 2023 According to a Rallybio media release, the company is planning for discussions with regulators later in 2023 or in the first half of 2024 in advance of the Phase 2 study.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com